Immunology
CXC Chemokine Receptor 4 Is a Cell Surface Receptor for Extracellular Ubiquitin*

https://doi.org/10.1074/jbc.M110.103408Get rights and content
Under a Creative Commons license
open access

Ubiquitin is one of the most highly conserved proteins in eukaryotes and plays major biological roles as a post-translational protein modifier. Ubiquitin is also a natural constituent of plasma, and several lines of evidence suggest that extracellular ubiquitin is an immune modulator with anti-inflammatory properties. In addition, ubiquitin treatment has been shown to limit inflammation and reduce organ injury in various disease models and species in vivo. However, its mechanism of action is unknown. Here we show that extracellular ubiquitin is a natural CXC chemokine receptor 4 (CXCR4 and CD184) agonist. Extracellular ubiquitin promotes intracellular Ca2+ flux and reduces cAMP levels through a G protein-coupled receptor that signals via a Gαi/o protein in THP1 cells. Toll-like receptor 4 stimulation reduces ubiquitin-binding sites, which enabled identification of four Gαi/o PCRs as ubiquitin receptor candidates. Overexpression of candidate genes in HEK293 cells, gene silencing in THP1 cells, competition binding, and signaling studies with the CXCR4 agonist stromal cell-derived factor-1α (chemokine (CXC motif) ligand 12) and inhibitor AMD3100 identify CXCR4 as a functional ubiquitin receptor. Our finding uncovers a fundamentally new aspect of the role of ubiquitin in biology, has implications for the understanding of CXCR4-mediated events, and is expected to facilitate development of new therapeutic avenues for a variety of diseases.

Cell Surface Receptor
G Protein-coupled Receptors (GPCR)
Immunology
Inflammation
Ubiquitin
CXC Chemokine Receptor 4
Stromal Cell-derived Factor-1α
Extracellular Ubiquitin

Cited by (0)

*

This work was supported by Deutsche Forschungsgemeinschaft Grant MA 2474/2-2 (to M. M.). This work was also supported in part by National Institutes of Health Grant GM075159 (to A. M.). The therapeutic use of ubiquitin has been patented (United States Patent 7,262,162), and M. M. is an inventor. Based on the results of this work, Loyola University Chicago has filed a provisional patent application (serial number 61/222,267). The authors are the inventors. None of the authors has received any income related to the patent or patent application.